HK Stock Market Move | AKESO (09926) rose more than 8%. The research results of Evosci HARMoni-6 will be published simultaneously in "The Lancet" and ESMO LBA.

AKESO (09926) rose more than 8%, rising by 6.97% as of the time of publication, reaching 130.5 Hong Kong dollars, with a turnover of 7.49 billion Hong Kong dollars. On the news front, according to an official announcement from AKESO, on October 16, the results of the phase III clinical study (AK112-306/HARMONi-6) of the globally pioneering bispecific antibody new drug developed independently by AKESO, Yivosi (PD-1/VEGF bispecific antibody) combined with chemotherapy compared with the therapy of single-agent pembrolizumab combined with chemotherapy in the frontline treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) have been accepted by the leading international medical journal, The Lancet, for publication at the 2025 European Society for Medical Oncology (ESMO 2025) Congress. The groundbreaking results are set to shine on the global scientific stage. It is reported that the study results have been successfully selected as ESMO Late-Breaking Abstract (LBA) for 2025 and will be presented at the most anticipated Presidential Symposium at the ESMO Congress by the principal investigator, Professor Lu Shun, Director of the Department of Oncology at Shanghai Chest Hospital. The oral presentation will showcase the remarkable results of the Yivosi combined with chemotherapy in a "head-to-head" phase III clinical study, comparing with the most widely used PD-1 combined with chemotherapy regimen in current cancer immunotherapy applications to the global oncology community.